Anti-Hypertensive Action of Fenofibrate via UCP2 Upregulation Mediated by PPAR Activation in Baroreflex Afferent Pathway

Neuroscience Bulletin
Jian GuanGuo-Fen Qiao

Abstract

Fenofibrate, an agonist for peroxisome proliferator-activated receptor alpha (PPAR-α), lowers blood pressure, but whether this action is mediated via baroreflex afferents has not been elucidated. In this study, the distribution of PPAR-α and PPAR-γ was assessed in the nodose ganglion (NG) and the nucleus of the solitary tract (NTS). Hypertension induced by drinking high fructose (HFD) was reduced, along with complete restoration of impaired baroreceptor sensitivity, by chronic treatment with fenofibrate. The molecular data also showed that both PPAR-α and PPAR-γ were dramatically up-regulated in the NG and NTS of the HFD group. Expression of the downstream signaling molecule of PPAR-α, the mitochondrial uncoupling protein 2 (UCP2), was up-regulated in the baroreflex afferent pathway under similar experimental conditions, along with amelioration of reduced superoxide dismutase activity and increased superoxide in HFD rats. These results suggest that chronic treatment with fenofibrate plays a crucial role in the neural control of blood pressure by improving baroreflex afferent function due at least partially to PPAR-mediated up-regulation of UCP2 expression and reduction of oxidative stress.

References

Jun 6, 2000·Nature·S KerstenW Wahli
Jan 27, 2005·The Journal of Pharmacology and Experimental Therapeutics·Reeba K VikramadithyanIra J Goldberg
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Apr 30, 2009·Brain Research·Keizo KanekoHideki Katagiri
Jun 19, 2009·Molecular and Cellular Biochemistry·Linda T TranJohn H McNeill
Jul 3, 2009·American Journal of Physiology. Cell Physiology·Guo-Fen QiaoJohn H Schild
Oct 28, 2009·European Journal of Pharmacology·Luz Ibarra-LaraAlicia Sánchez-Mendoza
Mar 10, 2010·The Journal of Physiology·Domitila A Huber, Ann M Schreihofer
Apr 28, 2010·Journal of Lipid Research·Maxwell A RubyRonald M Krauss
Nov 6, 2010·Diabetologia·T M E DavisUNKNOWN Fenofibrate Intervention and Event Lowering in Diabetes Study investigators
Jul 23, 2011·Arquivos brasileiros de endocrinologia e metabologia·Bianca Marmontel de SouzaDaisy Crispim
Sep 16, 2011·Trends in Molecular Medicine·Sabrina Diano, Tamas L Horvath
Feb 5, 2013·Journal of Advanced Pharmaceutical Technology & Research·Shipra SinghArun K Mishra
Feb 21, 2013·Nutrition Research and Practice·Jung Soo NamMyeong Ho Jung
Mar 19, 2013·Journal of Bioenergetics and Biomembranes·Susana CardosoPaula I Moreira
May 4, 2013·Journal of Cardiovascular Electrophysiology·Dominik LinzMichael Böhm
Jun 12, 2013·Biochimica Et Biophysica Acta·Anca D PetrescuFriedhelm Schroeder
Oct 9, 2013·Nature Medicine·Matthew Harms, Patrick Seale
Feb 12, 2014·Hypertension·Priscila S GuimaraesMaria Jose Campagnole-Santos
May 12, 2015·Free Radical Biology & Medicine·Daniel Gabriel PonsPilar Roca
Mar 10, 2016·Circulation·Louise C EvansMatthew A Bailey
Dec 25, 2016·American Journal of Physiology. Heart and Circulatory Physiology·Satoshi KaimotoSatoaki Matoba

❮ Previous
Next ❯

Methods Mentioned

BETA
Polymerase Chain Reaction
PCR
Infrared Imaging

Software Mentioned

LabChart

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.